Patented
Know-how based
Licensee
Development partner
Commercial partner
Investment
University spin out
There are no available human vaccines for preventing or treating Trypanosoma cruzi infections, which cause Chagas disease.
Researchers at Saint Louis University have identified T-cell targets relevant to human Trypanosoma cruzi infections. They identified 30 new immunogenic HLA-A2-restricted CD8+ T-cell epitopes.
The potential benefits of this technology include:
Increasing the number of treatments for Chagas disease
Minimizing the number of Trypanosoma cruzi infections
The potential applications of this technology include:
Preventing and treating Chagas disease
Saint Louis University is seeking a partner to further develop and commercialize this technology.